MAPT and Alzheimer disease: Prior findings have implicated IL-6 in mainstream AD-related neurodegenerative pathways such as amyloid deposition and plaque formation [[9], [10], [11]], tau hyperphosphorylation [47], and synaptic damage [48] (eFigure 1).